Christopher Baccei - Concepedia

Author

Christopher Baccei

Amplyx Pharmaceuticals (United States)

Also Known As

C Baccei, C.S Baccei, C.S. Baccei, Christopher Baccei, Christopher S Baccei, Christopher S. Baccei

Publications

Citations

H-Index

Concepts

All Affiliations

Amplyx Pharmaceuticals (United States)General Atomics (United States)Incept (United States)Merck & Co., Inc., Rahway, NJ, USA (United States)

About

Christopher Baccei is an author at Amplyx Pharmaceuticals (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	795
2	Natural Sciences	2	2	33
3	Social Sciences	2	2	523
4	Allergy	1	1	45
5	Allergy Medicine	1	1	45

Christopher Baccei

Publications

979

Citations

H-Index

Page 1

	Year	Citations
Effects of ketamine and n-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268 Daniel S. Lorrain, Christopher Baccei, Linda J. Bristow, Neuroscience PsychiatryNeurophysiologyNeurotransmitterRat Prefrontal CortexPsychopharmacology	2003	429
Group II mGlu Receptor Activation Suppresses Norepinephrine Release in the Ventral Hippocampus and Locomotor Responses to Acute Ketamine Challenge Daniel S. Lorrain, Hervé Schaffhauser, Una C. Campbell, Neuropsychopharmacology Locomotor ResponsesNeurophysiologyMedicineSynaptic TransmissionPhysiology	2003	94
Phenyl-tetrazolyl Acetophenones: Discovery of Positive Allosteric Potentiatiors for the Metabotropic Glutamate 2 Receptor Anthony B. Pinkerton, Jean‐Michel Vernier, Hervé Schaffhauser, Journal of Medicinal Chemistry Positive Allosteric PotentiatorsMglu2 Receptor PotentiatorsPharmacotherapyExperimental PharmacologyPositive Allosteric Potentiatiors	2004	58
Pharmacological Blockade of the DP2 Receptor Inhibits Cigarette Smoke-Induced Inflammation, Mucus Cell Metaplasia, and Epithelial Hyperplasia in the Mouse Lung Karin J. Stebbins, Alex Broadhead, Christopher Baccei, Journal of Pharmacology and Experimental Therapeutics	2009	48
5-Lipoxygenase-Activating Protein (FLAP) Inhibitors. Part 4: Development of 3-[3- <i>tert</i> -Butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1 <i>H</i> -indol-2-yl]-2,2-dimethylpropionic Acid (AM803), a Potent, Oral, Once Daily FLAP Inhibitor Nicholas Stock, Gretchen Bain, Jasmine Zunic, Journal of Medicinal Chemistry	2011	47
Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis Brian A. Stearns, Christopher Baccei, Gretchen Bain, Bioorganic & Medicinal Chemistry Letters InflammationAllergyAllergy MedicineMedicineMurine Model	2009	45
5-Lipoxygenase-Activating Protein Inhibitors: Development of 3-[3-<i>tert</i>-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1<i>H</i>-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103) John H. Hutchinson, Yiwei Li, Jeannie M. Arruda, Journal of Medicinal Chemistry	2009	41
A role for oleoylethanolamide in chronic lymphocytic leukemia Mojgan Masoodi, E Lee, Michael Eiden, Leukemia Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukemiaMedicineHematology	2014	27
In vitro and in vivo pharmacology of NXT629, a novel and selective PPARα antagonist Karin J. Stebbins, Alex Broadhead, Geraldine Cabrera, European Journal of Pharmacology Molecular PharmacologySelective Pparα AntagonistMedicinePhysiologyMechanism Of Action	2017	27
Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis Michael M. Poon, Kym I. Lorrain, Karin J. Stebbins, Proceedings of the National Academy of Sciences Inflammatory DemyelinationNeurodegenerative DiseasesMedicineNeurological FunctionEndogenous Remyelination	2024	26

Page 1